Biotech News

Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

Day One Biopharmaceuticals (DAWN)Day One Biopharmaceuticals2026-06-25 13:46 ESTClinical readout

OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid

Open original release

Related news

DAWNDay One Biopharmaceuticals2026-06-25 13:46 EST

Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

DAWNDay One Biopharmaceuticals2026-06-25 13:46 EST

Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

DAWNDay One Biopharmaceuticals2026-06-25 13:46 EST

Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference

DAWNDay One Biopharmaceuticals2026-06-25 13:46 EST

Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

DAWNDay One Biopharmaceuticals2026-06-25 13:46 EST

Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference

DAWNDay One Biopharmaceuticals2026-06-25 13:46 EST

Day One Completes Acquisition of Mersana Therapeutics

DAWNDay One Biopharmaceuticals2026-06-25 13:46 EST

Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance

DAWNDay One Biopharmaceuticals2026-06-25 13:46 EST

Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

DAWNDay One Biopharmaceuticals2026-06-25 13:46 EST

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

View all latest news

Day One Biopharmaceuticals

Day One Biopharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

DAWNDay One Biopharmaceuticals2026-06-26 08:47 EST

Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

DAWNDay One Biopharmaceuticals2026-06-26 08:47 EST

Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

DAWNDay One Biopharmaceuticals2026-06-26 08:47 EST

Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference

DAWNDay One Biopharmaceuticals2026-06-26 08:47 EST

Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

DAWNDay One Biopharmaceuticals2026-06-26 08:47 EST

Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States